1. Anti-SARS-CoV-2 Antibodies Persist for up to 13 Months and Reduce Risk of Reinfection
- Author
-
Arnaud Fontanet, Timothée Bruel, Yves Hansmann, Jérôme De Seze, Catherine Schmidt-Mutter, Samira Fafi-Kremer, Nathalie Reix, Delphine Planas, Aurélie Velay, Jean-Marc Lessinger, Anne Schneider, Baptiste Panaget, Laurence Kling-Pillitteri, Marialuisa Partisani, Olivier Schwartz, Morgane Solis, Floriane Gallais, Ludovic Glady, David Rey, Elodie Laugel, Nicolas Collongues, Nicolas Meyer, Pierre Gantner, Maria Candelaria Martin Gonzalez, Marie-Josée Wendling, and Sophie Bayer
- Subjects
biology ,business.industry ,Incidence (epidemiology) ,Arbitrary unit ,Antibody titer ,Virology ,Neutralization ,Persistence (computer science) ,Vaccination ,Interquartile range ,biology.protein ,Medicine ,Antibody ,business - Abstract
Assessment of the kinetics of SARS-CoV-2 antibodies is essential in predicting protection against reinfection and durability of vaccine protection. Here, we longitudinally measured Spike (S) and Nucleocapsid (N)-specific antibodies in 1,309 healthcare workers (HCWs), including 916 COVID-19 negative HCWs and 393 convalescent COVID-19 for up to 422 days post-symptom. From month (M)1 to M7-9 post-infection, SARS-CoV-2 antibodies decreased moderately in convalescent HCWs in a biphasic model, with men showing a slower decay of anti-N (p=0.02), and a faster decay of anti-S (p=0.0008) than women. At M11-13, anti-N dramatically decreased (half-life: 283 days) while anti-S stabilized (half-life: 725 days) at a median of 2.39 log Arbitrary Units (AU)/mL (Interquartile Range (IQR): 2.10 -2.75). Overall, 69 SARS-CoV-2 infections developed in the COVID-19 negative group (incidence of 12.22 per 100 person-years) versus one in the COVID-19 positive group (incidence of 0.40 per 100 person-years), indicating a relative reduction in the incidence of SARS-CoV-2 reinfection of 96.7% (p
- Published
- 2021
- Full Text
- View/download PDF